Have we achieved a Goldilocks grade of GVHD?

Post-transplantation cyclophosphamide (PTCy) has enabled near-universal donor access and expanded the pool of patients eligible for a haploidentical allogeneic transplant. While often used in combination with a calcineurin inhibitor (CNI), it can be used as sole GVHD prophylaxis in HLA-identical transplantation following myeloablative conditioning. Previous approaches using CNI-free approaches have included ex vivo T cell depletion (TCD) using immunomagnetic selection of CD34+ cells and in vivo TCD using antithymocyte globulin (ATG) [1,2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research